Digital Biomarker Lab​

See more, treat better.

We reveal meaningful health patterns from daily life through patient-centred digital biomarkers - supporting better treatment development, evaluation, and care.

Across everyday life, care pathways, and clinical studies, people generate rich signals about health, behaviour, and treatment response. Yet these signals are rarely captured, validated, or translated into evidence that patients, clinicians, and decision-makers can rely on. At the TNO Digital Biomarker Lab, we turn digital measures into trusted digital biomarkers that inform research, clinical development, and healthcare decisions.

How we create value:

• For patients – enable better outcomes and greater empowerment through measures that reflect daily life.
• For healthcare professionals – provide deeper insights to support more precise, informed treatment decisions.
• For pharmaceutical companies – support more efficient clinical development through fit-for-purpose digital measures.
• For MedTech innovators – accelerate technology adoption by generating credible, real-world evidence.

The challenge: why digital biomarkers matter

Traditional clinical measures are episodic and often burdensome, capturing only a limited snapshot of a person’s health. Important information about how people function, respond to treatment, and recover between visits remains insufficiently captured. Unlike the traditional assessments, digital biomarkers can capture health continuously and in real-world settings, providing insight into how people function and feel in their daily lives

At the same time, the term digital biomarker is used inconsistently. In regulated contexts, digital biomarkers, which are defined by the FDA as objective, quantifiable digital measures,  must be analytically, clinically, and usability validated before they can support decision-making. In practice, many initiatives generate digital data without the evidence needed for trust, adoption, or scale.

Development efforts are often fragmented across discovery, validation, usability, and data infrastructure, making it difficult to move from promising signals to real-world implementation.

A vast amount of potential remains untapped.

Our solution: the TNO approach

The TNO Digital Biomarker Lab helps organisations turn digital measures into evidence they can trust and act on.

Our approach is rigorous, independent, and patient-centred. We align scientific methods, technology, and collaboration to ensure digital biomarkers are developed and validated for their specific research or development context.

By combining discovery, validation, patient engagement, and data infrastructure, we enable organisations to build digital biomarkers that are robust, interpretable, and ready to be used, whether in clinical development, healthcare practice, or real-world settings.

Trusted expertise

Building on more than 20 years of experience measuring health and behaviour, TNO combines scientific depth with practical expertise in digital health and clinical research. As an independent, regulator-aware partner, we collaborate with pharmaceutical and MedTech companies, healthcare providers, and patient organisations and engage with regulators and policymakers to support the responsible adoption of digital biomarkers.

Digital biomarker's portfolio

Turning evidence into impact: our projects and partnerships.

The TNO Digital Biomarker Lab builds on TNO’s long-standing expertise in measuring health and behaviour, combined with the team’s focused experience over the past years in digital biomarker development across multiple therapeutic areas.

Our projects span chronic inflammatory, cardiovascular, metabolic, neurological, and sleep-related conditions, and are carried out in close collaboration with partners from industry, academia, and healthcare.

Through scientific rigour and fit-for-purpose digital measures, we translate complex sensor-derived data into meaningful evidence that supports innovation in medicine.

Lets work together to accelerate digital health innovation

We collaborate with pharmaceutical, MedTech, and healthcare partners to advance digital biomarker development – from early discovery to validation and deployment – in various collaboration modes:

• Joint research and development projects
• Industry partnerships and service contracts
• Clinical validation and pilot studies
• Strategic advisory and training